ClinicalTrials.gg
Not yet recruitingNCT07747805GLIMR COPDUpdated Aug 5, 2026

GLP-1 Agonists for Lung Function Improvement and Muscle Restoration in COPD

A Phase 2 interventional study of Tirzepatide in COPD, Obesity & Overweight and Sarcopenia, sponsored by The Cleveland Clinic. Not yet recruiting at 1 site in United States. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by The Cleveland Clinic · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 1,279 studies in Pulmonary Disease, Chronic Obstructive with a site in United States — 138 open to participants now, 173 under way, 20 of them phase 3. Pulmonary Disease, Chronic Obstructive · United States.

Planned enrollment
749th of 1,038
30 · median 100
Started
2026
with 39 others
Phase 2
193 of 1,279
16 open now
Primary completion
2028-08
later than 119 of 172 live
Registered
1,263rd of 1,279
by date

Among the 1,279 studies in Pulmonary Disease, Chronic Obstructive with a site in United States, this one is the 749th largest by planned enrollment of the 1,038 interventional ones that give a count, is one of 40 that started in 2026, is one of 193 in phase 2, reaches primary completion later than 119 of the 172 other live ones, and was the 1,263rd registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

138 of the 1,279 studies in Pulmonary Disease, Chronic Obstructive with a site in United States are open now. Recruiting first, the newest first:

133 more — sign in →

All 138 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,279 studies in Pulmonary Disease, Chronic Obstructive with a site in United States, or all of them as a file.
02

Study summary

Chronic obstructive pulmonary disease (COPD) is associated with systemic inflammation, obesity-related metabolic dysfunction, skeletal muscle impairment, and progressive decline in lung function. While obesity has historically been viewed as protective in COPD, emerging evidence suggests that excess adiposity and adipokine dysregulation, particularly elevated leptin levels, contribute to chronic inflammation, impaired muscle function, and worse clinical outcomes. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated anti-inflammatory, metabolic, and potential muscle-preserving effects beyond weight loss, making them promising therapeutic candidates for COPD.

The GLIMR COPD study is a prospective, randomized, controlled pilot trial designed to evaluate the effects of tirzepatide on lung function, skeletal muscle health, inflammation, and body composition in overweight and obese adults with COPD. Thirty participants will be enrolled at the Cleveland Clinic COPD Center, including 20 participants receiving tirzepatide and 10 age- and sex-matched control participants. Study participants will be followed for 12 months with assessments performed at screening, baseline, 6 months, and 12 months. Tirzepatide-treated participants will undergo standard dose escalation to a maintenance dose of 2.4 mg weekly.

The primary objective is to determine the effect of GLP-1 receptor agonist therapy on skeletal muscle function and physiology over 12 months. Secondary objectives include evaluating changes in body composition, systemic inflammation, adipokine signaling, immune function, pulmonary physiology, physical performance, and treatment tolerability.

The study is built around three mechanistic aims. First, we will characterize the effects of GLP-1 therapy on systemic inflammation and immune dysregulation using longitudinal blood-based proteomic analyses and adipokine measurements, including leptin and adiponectin. Second, we will investigate the impact of GLP-1 therapy on skeletal muscle mitochondrial function and fatty acid oxidation using muscle biopsies obtained at baseline and 12 months, combined with high-resolution respirometry, transcriptomics, metabolomics, and proteomics. Third, we will assess changes in clinical outcomes including lung function, body composition, muscle strength, and physical performance.

Participants will undergo comprehensive phenotyping that includes spirometry, respiratory muscle strength testing, six-minute walk testing, handgrip strength, sit-to-stand testing, body composition assessment, diaphragm ultrasound, and non-contrast CT imaging of the lungs and thighs. Blood samples will be collected for biomarker, proteomic, metabolomic, genomic, and immunologic analyses. Vastus lateralis muscle biopsies will be performed at baseline and study completion to evaluate mitochondrial bioenergetics and molecular pathways associated with muscle remodeling.

Eligible participants will be adults aged 40-80 years with COPD, a smoking history of at least 10 pack-years, and overweight or obesity. Individuals with diabetes, active malignancy, recent COPD exacerbations, contraindications to tirzepatide, or conditions that could interfere with study participation will be excluded.

This pilot study is designed to generate critical mechanistic and clinical data regarding the role of GLP-1 receptor agonists in COPD. Findings will help define the relationships among obesity, adipokine signaling, systemic inflammation, skeletal muscle dysfunction, and lung disease progression, while providing preliminary efficacy estimates to support the design of a future multicenter randomized clinical trial evaluating GLP-1 therapy as a novel treatment strategy for COPD.

Read the detailed description

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide and is increasingly recognized as a systemic disease that affects far more than the lungs. In addition to airflow limitation, many individuals with COPD experience chronic inflammation, loss of skeletal muscle function, reduced exercise capacity, and metabolic abnormalities that contribute substantially to disability, hospitalizations, and reduced quality of life. Obesity, which is highly prevalent among patients with COPD, further worsens these systemic manifestations through complex interactions involving inflammation, altered hormone signaling, and impaired energy metabolism. Despite the significant burden imposed by these metabolic and musculoskeletal complications, few therapies specifically target the underlying biological pathways that connect obesity, inflammation, muscle dysfunction, and lung disease.

The GLIMR COPD study is a randomized, controlled pilot clinical trial designed to investigate whether treatment with the GLP-1/GIP receptor agonist tirzepatide can improve lung function, skeletal muscle health, physical performance, and systemic inflammation in overweight and obese individuals with COPD. Beyond its established effects on weight reduction and glucose regulation, tirzepatide has demonstrated potent anti-inflammatory and metabolic benefits that may favorably influence multiple biological pathways involved in COPD progression. Emerging evidence suggests that GLP-1-based therapies can reduce inflammatory signaling, improve mitochondrial function, enhance skeletal muscle metabolism, and alter adipokine profiles, including reductions in circulating leptin, a hormone that has been strongly associated with worse COPD outcomes.

The study will enroll 30 participants with COPD, including 20 individuals receiving tirzepatide and 10 age- and sex-matched control participants. Participants will undergo detailed evaluations at baseline, six months, and twelve months. These assessments will include pulmonary function testing, exercise capacity measurements, muscle strength testing, body composition analysis, imaging studies, blood biomarker analyses, and skeletal muscle biopsies. By combining clinical assessments with advanced molecular analyses, the study seeks to understand not only whether tirzepatide improves health outcomes, but also the biological mechanisms responsible for those improvements.

The first objective of the study is to determine how tirzepatide influences systemic inflammation and immune dysfunction in COPD. Blood samples collected throughout the study will undergo comprehensive proteomic and biomarker analyses to identify changes in inflammatory pathways and circulating mediators associated with treatment. Particular attention will be given to adipokines such as leptin and adiponectin, which may serve as important links between obesity and COPD progression.

The second objective is to investigate the effects of tirzepatide on skeletal muscle health. Skeletal muscle dysfunction is a major contributor to exercise intolerance and reduced quality of life in COPD. Muscle biopsies obtained before and after treatment will be used to evaluate mitochondrial function, fatty acid oxidation, gene expression, protein signaling, and metabolic pathways that regulate muscle performance and adaptation. These studies will provide important insights into whether tirzepatide directly improves muscle bioenergetics and cellular health.

The third objective is to quantify the effects of tirzepatide on clinically meaningful outcomes. Investigators will assess changes in lung function, respiratory muscle strength, exercise capacity, muscle strength, physical performance, and body composition. Advanced CT imaging will be used to measure changes in skeletal muscle mass, visceral fat, and other body composition characteristics. These measurements will help determine whether improvements in metabolic health translate into better physical function and pulmonary outcomes.

Participants eligible for enrollment will be adults aged 40-80 years with COPD and overweight or obesity. The study is being conducted through the Cleveland Clinic COPD Center, which follows more than 2,500 patients and has extensive experience in COPD clinical research and translational investigations.

The long-term goal of this project is to establish a scientific foundation for larger multicenter clinical trials evaluating incretin-based therapies as novel treatment strategies for COPD. By examining the interconnected relationships among obesity, inflammation, skeletal muscle dysfunction, and lung disease, this study has the potential to identify new therapeutic approaches that address both pulmonary and systemic manifestations of COPD. The findings may ultimately help improve physical function, quality of life, and long-term outcomes for millions of individuals living with COPD.

03

Conditions studied

  • COPD
  • Obesity & Overweight
  • Sarcopenia

Keywords

  • COPD
  • sarcopenia
  • obesity
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 40-80 years
  • Diagnosis of (COPD) with post-bronchodilator /FVC \< 0.70
  • GOLD stage 1-3 COPD (FEV₁ >30% predicted)
  • Former smoker with a smoking history of at least 10 pack-years
  • (BMI) ≥27 kg/m² with at least one weight-related comorbidity (e.g., prediabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease) or BMI 30-40 kg/m²
  • Able and willing to provide written
  • Able to comply with study procedures and follow-up visits

Exclusion criteria

Exclusion Criteria:

  • Type 2 diabetes mellitus ( > 6.5%)
  • Pregnancy or breastfeeding
  • Coagulopathy, defined as > 1.4 or count \<80,000/μL
  • Active , including lung cancer
  • Use of medications known to significantly alter muscle protein metabolism within 6 weeks of enrollment (e.g., oral , tamoxifen, high-dose estrogen, testosterone)
  • Personal or family history of medullary thyroid carcinoma
  • Multiple endocrine neoplasia syndrome type 2 (MEN2)
  • Known or to tirzepatide or its components
  • History of pancreatitis
  • Severe gastrointestinal disease that, in the opinion of the investigator, would increase risk from study participation
  • Significant diabetic retinopathy
  • renal impairment
  • Clinically significant gallbladder disease
  • Current treatment with a DPP-4 inhibitor
  • exacerbation within 60 days prior to enrollment
  • Participation in pulmonary rehabilitation within 2 weeks prior to enrollment
  • Any medical, psychiatric, or social condition that, in the opinion of the investigators, may interfere with study participation, adherence to study procedures, or participant safety
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • No intervention
    COPD control

    Participants with COPD and overweight or obesity who will not receive tirzepatide and will continue standard clinical care. Participants will complete the same research assessments as the intervention group, including blood collection, pulmonary function testing, physical performance testing, body composition assessments, imaging, and skeletal muscle biopsies, allowing comparison of clinical and biological changes over 12 months.

  • Active comparator
    COPD tirzepatide treatment

    Participants with COPD and overweight or obesity will receive once-weekly subcutaneous tirzepatide for 52 weeks in addition to standard clinical care. Participants will undergo longitudinal assessments of lung function, skeletal muscle health, body composition, physical performance, and inflammatory biomarkers to evaluate the effects of tirzepatide on pulmonary and systemic manifestations of COPD.

    Drug: Tirzepatide

Interventions

  • Tirzepatide is a once-weekly subcutaneous dual GIP/GLP-1 receptor agonist administered for 52 weeks using standard dose escalation as tolerated in addition to standard clinical care.

06

What researchers measure

Primary outcomes

  1. Change in FEV1

    Change in post-bronchodilator forced expiratory volume in one second (FEV₁) measured by standardized spirometry. FEV₁ will be compared between participants receiving tirzepatide and control participants.

    Time frame: 12 months

Secondary outcomes

  1. Change in Hand Grip Strength

    Change in dominant hand grip strength measured using a calibrated hand dynamometer.

    Time frame: 6 months and 12 months

  2. Change in Six-Minute Walk Distance (6MWD)

    Change in time required to complete five chair rises as a measure of lower extremity muscle function and mobility.

    Time frame: 6 months and 12 months

  3. Change in Five Sit-to-Stand Performance

    Change in time required to complete five chair rises as a measure of lower extremity muscle function and mobility.

    Time frame: 6 months and 12 months

  4. Change in Lean Muscle Mass

    Change in skeletal muscle mass quantified by CT imaging and bioimpedance analysis.

    Time frame: 12 months

  5. Change in Serum Leptin Concentration

    Change in circulating leptin concentration measured from fasting blood samples.

    Time frame: 6 months and 12 months

  6. Change in Skeletal Muscle Mitochondrial function

    Change in mitochondrial respiratory capacity measured in vastus lateralis muscle biopsy specimens.

    Time frame: 12 months

07

Study locations

1 site
08

References and documents

Publications

  • Hong Y, Lee JH, Jeong KW, Choi CS, Jun HS. Amelioration of muscle wasting by glucagon-like peptide-1 receptor agonist in muscle atrophy. J Cachexia Sarcopenia Muscle. 2019 Aug;10(4):903-918. doi: 10.1002/jcsm.12434. Epub 2019 Apr 24. PubMed 31020810 ↗
  • Foer D, Strasser ZH, Cui J, Cahill KN, Boyce JA, Murphy SN, Karlson EW. Association of GLP-1 Receptor Agonists with Chronic Obstructive Pulmonary Disease Exacerbations among Patients with Type 2 Diabetes. Am J Respir Crit Care Med. 2023 Nov 15;208(10):1088-1100. doi: 10.1164/rccm.202303-0491OC. PubMed 37647574 ↗

Individual participant data

Plan to share: No — There is no current plan to share individual participant data outside the study team. Any future data sharing will be considered in accordance with participant consent, institutional policies, and regulatory requirements.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Aug 2028, 23 months later.

Of 47 non-industry phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 63. This study's planned 23 months is below that.

Counting every sponsor, half of 166 studies reached it within 17 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2026
First posted
Aug 5, 2026
StartEst.
Aug 28, 2026
Primary completionEst.
Aug 15, 2028
CompletionEst.
Aug 15, 2029
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07747805
Responsible party
Amy Attaway (Staff, The Cleveland Clinic) — Principal investigator
First posted
Aug 5, 2026
Start date
Aug 28, 2026 (estimated)
Primary completion
Aug 15, 2028 (estimated)
Completion
Aug 15, 2029 (estimated)
Last update
Aug 5, 2026

Study contacts

Amy Attaway, MD
Contact
attawaa@ccf.org
216-445-2807
Lian Yang
Contact
YANGL2@ccf.org
216-445-5441
Amy Attaway, MD
principal investigator · The Cleveland Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion